Allovir Inc
For the period ended Jun 30, 2024. Filed Aug 9, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 9, 2024
KLRS$1.87-18.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| Six Months EndedJune 30, | ||
|---|---|---|
| (in thousands) | 2024 | 2023 |
| Cash flows from operating activities | ||
| Net loss | $(36,375) | $(86,450) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | — | 171 |
| Non-cash lease expense | 145 | 233 |
| Non-cash gain on lease termination and remeasurement | (7,364) | — |
| Accretion of short-term investment discounts | (1,127) | (1,253) |
| Stock-based compensation expense | 10,942 | 20,317 |
| Changes in operating assets and liabilities: | ||
| Interest receivable | 110 | 51 |
| Prepaid expenses and other current assets and prepaid expenses to related party | 3,256 | 2,856 |
| Other assets | 122 | (72) |
| Income tax payable | — | (1) |
| Accounts payable, accrued expenses, other liabilities and amount due to related party | (25,408) | 4,908 |
| Net cash used in operating activities | (55,699) | (59,240) |
| Cash flows from investing activities | ||
| Purchase of short-term investments | — | (14,196) |
| Maturities of short-term investments | 70,000 | 93,814 |
| Net cash provided by investing activities | 70,000 | 79,618 |
| Cash flows from financing activities | ||
| Proceeds from issuance of common stock in public offering, net of underwriting discounts, commissions and offering costs | — | 70,169 |
| Proceeds from issuance of stock under the 2020 Employee Stock Purchase Plan | 21 | 315 |
| Net cash provided by financing activities | 21 | 70,484 |
| Net increase in cash, cash equivalents, and restricted cash | 14,322 | 90,862 |
| Cash, cash equivalents, and restricted cash at beginning of period | 90,973 | 106,944 |
| Cash, cash equivalents, and restricted cash at end of period | $105,295 | $197,806 |
| Non-cash investing and financing activities | ||
| Unrealized (loss) gain on available-for-sale securities | $(77) | $243 |
| Deferred offering costs included in accounts payable and accrued expenses | $— | $331 |
| Reduction of right-of-use asset due to modification and remeasurement | $1,549 | $— |
| Supplemental disclosure of cash flows | ||
| Income taxes paid, net of refunds | $— | $350 |
| Six Months EndedJune 30, | ||
| 2024 | 2023 | |
| Cash and cash equivalents | $104,741 | $196,954 |
| Restricted cash | 554 | 852 |
| Total cash, cash equivalents, and restricted cash | $105,295 | $197,806 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.